Tong Ren Tang Technologies CoTGRNF 50 Return-on-Tangible-Equity is 1.61% as of Dec. 2025, which is 82% below its 10-year median of 8.86. GuruFocus rates TGRNF with a GF Score™ of 50/100 and a GF Value™ of $0.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 898 Drug Manufacturers companies, Tong Ren Tang Technologies Co ranks worse than 56.68% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tong Ren Tang Technologies Co's annualized net income for the quarter that ended in Dec. 2025 was $16.4 Mil. Tong Ren Tang Technologies Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $1,018.8 Mil. Therefore, Tong Ren Tang Technologies Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 1.61%.
The historical rank and industry rank for Tong Ren Tang Technologies Co's Return-on-Tangible-Equity or its related term are showing as below:
TGRNF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.53 Med: 8.86 Max: 15.1
Current: 5.53
During the past 13 years, Tong Ren Tang Technologies Co's highest Return-on-Tangible-Equity was 15.10%. The lowest was 5.53%. And the median was 8.86%.
TGRNF's Return-on-Tangible-Equity is ranked worse than 56.68% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs TGRNF: 5.53
Tong Ren Tang Technologies Co (OTCPK:TGRNF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tong Ren Tang Technologies Co Return-on-Tangible-Equity Related Terms
Tong Ren Tang Technologies Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tong Ren Tang Technologies Co Return-on-Tangible-Equity Chart
TGRNF vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.61% mean?
Tong Ren Tang Technologies Co (TGRNF) has a Return-on-Tangible-Equity of 1.61% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tong Ren Tang Technologies Co and its competitors. This is 82% below median its historical median of 8.86. Over the past decade, Tong Ren Tang Technologies Co's Return-on-Tangible-Equity has ranged from 5.53 to 15.10. According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #509 out of 898 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is Tong Ren Tang Technologies Co's Return-on-Tangible-Equity too high?
Tong Ren Tang Technologies Co's current Return-on-Tangible-Equity of 1.61% is 82% below median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 5.53 to a high of 15.10. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Tong Ren Tang Technologies Co's value of 1.61% is 79.6% below this industry median. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #509 out of 898 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #509 out of 898 companies for Return-on-Tangible-Equity. This places Tong Ren Tang Technologies Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.88. Tong Ren Tang Technologies Co's value of 1.61% is 79.6% below this benchmark. Historically, Tong Ren Tang Technologies Co's own Return-on-Tangible-Equity has ranged from 5.53 to 15.10 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 7.88, Tong Ren Tang Technologies Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tong Ren Tang Technologies Co's current Return-on-Tangible-Equity of 1.61% is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tong Ren Tang Technologies Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current Return-on-Tangible-Equity is 1.61%, which is 82% below median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co (TGRNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.84, compared to a current price of $0.49 — trading 41.1% below its estimated fair value. The current Return-on-Tangible-Equity is 1.61%, which is 82% below median its 10-year median of 8.86 and 79.6% below the Drug Manufacturers industry median of 7.88. Tong Ren Tang Technologies Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current Return-on-Tangible-Equity is 1.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 41.1% below its estimated GF Value™ of $0.84.
GuruFocus considers Tong Ren Tang Technologies Co to be Significantly Undervalued.
Key valuation signals for TGRNF:
Return-on-Tangible-Equity: 1.61% (82% below median its 10-year median of 8.86)
GF Value™: $0.84 vs. price of $0.49 (41.1% below fair value)
Industry Position: 79.6% below the Drug Manufacturers median (#509 of 898)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Business Description
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
50GF Score
Get the complete analysis for TGRNF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
